Trial reportDiabetes, obesity & metabolism2021
A phase 3 randomized clinical trial using a once-weekly glucagon-like peptide-1 receptor agonist in adolescents and young adults with hypothalamic obesity.
Trial report in Diabetes, obesity & metabolism, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 5 syntheses or guidelines pooled it, 75 citations in OpenAlex.
- The Efficacy of Pharmacotherapy Intervention on Anthropometric Outcomes in Survivors of Childhood Brain Tumors: An Updated Systematic Review and Meta-Analysis.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2026Pooled it
- Body Composition and Lifestyle Interventions in Pharmacological Treatment of Acquired Hypothalamic Obesity: A Systematic Review of Randomized Controlled Trials.Obesity (Silver Spring, Md.) · 2026Pooled it
- Effect of weight loss interventions on liver-related health in children and adolescents with obesity: a systematic review and meta-analyses.International journal of obesity (2005) · 2026Pooled it
- Efficacy and Safety of GLP-1 RAs in Children and Adolescents With Obesity or Type 2 Diabetes: A Systematic Review and Meta-Analysis.JAMA pediatrics · 2025Pooled it
- Exenatide for obesity in children and adolescents: Systematic review and meta-analysis.Frontiers in pharmacology · 2024Pooled it
- Liraglutide for Weight Management in Children and Adolescents With Prader-Willi Syndrome and Obesity.The Journal of clinical endocrinology and metabolism · 2022 · on this mapTrial
- Randomized controlled trial of Tesomet for weight loss in hypothalamic obesity.European journal of endocrinology · 2022Trial
- MRI measures of hypothalamic injury are associated with glucagon-like peptide-1 receptor agonist treatment response in people with hypothalamic obesity.Diabetes, obesity & metabolism · 2021Trial
- A phase 3 randomized clinical trial using a once-weekly glucagon-like peptide-1 receptor agonist in adolescents and young adults with hypothalamic obesity.Diabetes, obesity & metabolism · 2021Trial
- Safety and effectiveness of setmelanotide in young patients with severe obesity due to craniopharyngioma: a real world monocentric experience.Journal of endocrinological investigation · 2026Article
- Approach to the patient with acquired hypothalamic syndrome.The Journal of clinical endocrinology and metabolism · 2026Review
- Pharmacologic and Non-Pharmacologic Interventions for Hypothalamic Obesity: An Updated Review.Current obesity reports · 2026Review
- Current Approaches and Therapeutic Strategies for Hypothalamic Syndrome in Patients with Childhood-onset Craniopharyngioma.Journal of clinical research in pediatric endocrinology · 2026Review
- SEMASEARCH Study Design: Real-World Evaluation of Semaglutide 2.4 mg in Adults With Severe Obesity Underrepresented in Clinical Trials.Diabetes, obesity & metabolism · 2026Observational
- Semaglutide use for hypothalamic obesity and type 2 diabetes mellitus after suprasellar germinoma treatment.JCEM case reports · 2026Article
- Review
- Appetite sensations and hormonal secretion in patients with adamantinomatous craniopharyngioma.Journal of endocrinological investigation · 2026Article
- Obesity medications and acquired hypothalamic obesity in adults: A two-case experience.Obesity pillars · 2026Article
- Hunger, satiety, and eating behavior after craniopharyngioma - narrative review on current management and future therapeutic perspectives.Frontiers in endocrinology · 2026Review
- Effectiveness and safety of GLP-1 receptor agonists in craniopharyngioma patients with obesity: A multicentre real-world study.Diabetes, obesity & metabolism · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 1 country.
Funding
Abstract
aimTo evaluate the efficacy, safety and tolerability of a glucagon-like peptide-1 receptor agonist (GLP-1 RA) in patients with hypothalamic obesity (HO). MATERIALS AND
methodsA two-arm, randomized, multicentre, double-blind, placebo-controlled trial was conducted in 10- to 25-year-olds with hypothalamic injury following intracranial tumour and HO. Participants were randomized to once-weekly subcutaneous injections of a GLP-1 RA exenatide 2 mg (ExQW) or placebo for 36 weeks. The primary efficacy endpoint was 36-week % change in body mass index (BMI). Secondary outcomes included change in body composition (by dual energy x-ray absorptiometry).
resultsForty-two participants were randomized to ExQW (n = 23) or placebo (n = 19). Participants were 5 ± 2 years (mean ± SD) postdiagnosis and development of HO (BMI 37.3 ± 7.1 kg/m
conclusionsGLP-1 RAs are a promising and safe treatment to improve or stabilize HO in children and young adults.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.